Mirion Technologies(MIR) - 2021 Q4 - Annual Report

Financial Performance - The Business Combination consideration paid by the Company to pre-Business Combination stockholders was approximately $1.3 billion in cash, along with 30,401,902 newly issued shares of Class A common stock and 8,560,540 newly issued shares of Class B common stock[31]. - Approximately 19.5% of GSAH's issued and outstanding Class A common stock was redeemed by stockholders prior to the Business Combination[28]. - The Company’s financial performance is driven by the replacement of products and recurring services in core end markets, as well as the construction of new nuclear power plants globally[27]. - Approximately 45% of total revenue for fiscal 2021 came from sales to customers outside the United States and Canada, highlighting the company's global footprint and market reach[78]. - Total backlog as of December 31, 2021, was$ 747.5 million, an increase from $715.8 million on June 30, 2021[92]. - Deferred contract revenue increased to$ 73.0 million as of December 31, 2021, compared to $50.4 million on June 30, 2021[92]. - Approximately 45% of the backlog is expected to be recognized in calendar year 2022[91]. - The top five customers accounted for approximately 14% of consolidated revenue during the reporting periods[101]. Market Opportunities - The Company aims to capitalize on growth opportunities in medical, defense, and nuclear power sectors[26]. - The global nuclear medicine market is expected to grow approximately 7% per year from 2020 through 2030, driven by the increase in cancer prevalence and incidences[58]. - The global radiotherapy market is projected to grow approximately 6% per year from 2020 through 2030, influenced by growing awareness and technological advancements[58]. - The core dosimetry market is expected to grow 3 to 4% per year from 2020 through 2026, driven by an increase in healthcare workers exposed to radiation[59]. - The existing global installed base of nuclear reactors has a median age of 34 years, necessitating frequent product replacements and upgrades[65]. - The total number of nuclear power plant shutdowns under decontamination and decommissioning is expected to increase over the next decade, particularly in the U.S. market[66]. - The global nuclear reactor construction market is expected to grow, with 57 reactors currently under construction and 423 planned or proposed, providing significant revenue opportunities for the company[69]. - The company aims to exploit under-penetrated market opportunities, particularly in the U.S. dosimetry services market and the nuclear sector in Europe[81]. Product Development and Innovation - The Company has successfully leveraged its expertise in ionizing radiation to drive innovation and expand commercial applications[22]. - New product development includes the evrCAM for radiation oncology, leveraging core technology from the nuclear power industry[83]. - The company has developed a new personal radiation detector, Accurad, to expand its presence in civil services markets such as police and fire departments[84]. - The company has successfully integrated fourteen acquisitions since 2016, enhancing its product offerings and market presence in the radiation detection sector[79]. Regulatory Compliance - The company is subject to various environmental regulations, including the Comprehensive Environmental Response, Compensation and Liability Act, which may impose future remediation expenditures[117]. - The company must comply with the Resource Conservation and Recovery Act, which regulates hazardous waste management and imposes civil liabilities for non-compliance[117]. - The company is subject to inspections by the Nuclear Regulatory Commission to ensure compliance with safety and quality assurance regulations in the nuclear power industry[131]. - The company holds numerous licenses for radioactive materials across various jurisdictions, with typical license terms ranging from two to five years[129]. - The company incurs costs associated with obtaining and maintaining approvals for medical devices from regulatory bodies such as the FDA and the European Medicines Agency[147]. - Medical devices must comply with the FDA's regulations, including safety and effectiveness standards, and any significant changes may require new approvals[149]. - The company must navigate complex regulatory requirements for marketing medical devices in non-U.S. countries, which can vary significantly[154]. - Compliance with privacy and information security laws, such as the GDPR and CCPA, is essential for the company as it processes personal information[161]. Workforce and Operations - The engineering and research and development organization consists of 356 scientists, engineers, and technicians, representing approximately 14% of the workforce as of December 31, 2021[26]. - The company employed 2,630 full-time and part-time employees as of December 31, 2021[105]. - The production personnel consisted of 1,176 employees, representing approximately 45% of the total workforce as of December 31, 2021[102]. - The company has a seasoned management team with an average tenure of over 15 years, supported by a skilled engineering and R&D organization of 356 professionals[80]. - The company has 30 sales offices across North America, Europe, and Asia as of December 31, 2021[96]. Economic Factors - The company is experiencing inflationary pressure on operating costs, including increased personnel costs and higher commodity prices[601]. - Freight costs for inbound and outbound shipments have increased, expected to persist into 2022[602]. - A hypothetical 10% change in foreign currencies would have impacted revenues by approximately$ 8.7 million during the Successor Period[598]. - The effect of a hypothetical 1% change in exchange rates would have impacted accumulated other comprehensive income by approximately $2.5 million during the Successor Period[599]. - If market interest rates increase by 100 basis points, year-to-date interest expense would increase by approximately$ 8.4 million[600]. - Changes in foreign exchange rates could impact the price and demand for products, affecting competitiveness[599]. Compliance and Legal Risks - The company is affected by multi-jurisdictional legal and regulatory environments, which impose extensive and changing laws governing its operations[121]. - The company is subject to various economic sanctions imposed by the U.S. Treasury Department's Office of Foreign Assets Control (OFAC), which restrict transactions with certain countries and entities[138]. - Violations of U.S. export control regulations or OFAC sanctions can lead to significant penalties, including criminal and civil fines, imprisonment, and loss of export privileges[140]. - The company has implemented compliance policies and procedures to address challenges related to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act[144].